Suitable preclinical models are needed to evaluate therapies targeting specific pathways which affect brain cancer. Patient Derived Xenograft (PDX) models are known to closely reflect human heterogeneity and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. The CrownBio brain cancer PDX collection consists a wide range of models, including several orthotopic models to more closely recapitulate the tumor microenvironment. More
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.